Get started

NVAX

BNTX biotech / currency play LONGBNTX a Germany company in the biotechnology and vaccine sectors out of Europe and Germany is looking good on the 2H chart here with a volume profile and an intermediate term VWAP overlaid. Price bounced off the bottom of the high volume area of the volume profile and looks to be ready for a reversion to the mean and even a sling-short move. The target here is the double top M pattern of mid July at 114. The VPT and MACD are confirmatory of a momentum flip making for a long trade entry. I will review the options chain for a suitable options trade with a narrow bid/ask spread, suitable volume and open interest. If I cannot find one I'll take a trade of 10-20 shares of stock with a stop-loss of 105 to back up this trade while NVAX and MRNA are also making moves.
NASDAQ:BNTXLong
by AwesomeAvani
MRNA a medical Technology Stock LONG MRNA is a medical technology company. It is in the vaccine sector and competes ( well) with NVAX and PFE among others. Earnings are upcoming on 8/3 in about a week. On the 30 minute chart it appears to be in a descending wedge pattern which is typically a bottoming with a breakout over and beyond the descending trendline. The relative trend indicator shows the downtrend to be a slow grinding type trend with some minor corrections along the way. As might be expected the RS lines are low in the indicator's channel. I see this as a setup for a pre-earnings play with the expectation that MRNA could breakout above the resistance trend line and move toward the horizontal resistance of the triple top earlier in mid-July. I see medical stocks as a good alternative to technology stocks that may be overextended and stressed by the current financial chaos pressuring the markets. Another approach is a two call options targeting $ 125 expiring 8/11 and running the first until 100% profit or 8/2, the day before the expiration whichever comes first and letting the other run through earnings into the middle of the following week at 8/9. I always like to cut these short of expiration by a few days to diminish the effects of time decay.
NASDAQ:MRNA
by AwesomeAvani
2
Can VBIV jump again like earlier this month?VBIV popped 50 % to begin July and then promptly lost 75% and has been low volume and sideways since. I have not been able to discern any catalyst for that action. Earnings show an ongoing cash burn. In the past couple of days, the Price Volume Trend indicator has detected a small increase in the price volume product. The Relative Trend Index (RTI) indicator has gone from negative to positive on July 18th while the dual time frame RSI indicator showing 1 hour TF in blue and daily TF in black has shown bullish divergence with the lines rising over the 50 level and the blue line above the black line. Price crossed a VWAP band line on July 18th as well. The analysis supports a bullish bias and a set up for a long trade. I will trade long and find an entry on a 15 - 30 minute chart looking for a pivot low to take that position. I will target 2.25 and 3.00 for the time being.
VLong
by AwesomeAvani
1
Will Novavax NVAX go higher? SHORTNVAX popped today for a price jump of more than 20%. Canada agreed to pay out on a contract for COVID vaccines it now does not want in the amount of $350M. This is hardly enough to the fundamentals of the company overall. So the question arises, have traders and / or investors overreacted to a one time bonus which is essentially revenue without overhead and expense. My opinion is that this is an overreaction and that the price will drop after the pop hits a high. Buying long right now is essentially the risk of buying a high that will not go higher. On the Chris Moody dual RSI indicator, the longer one hour TM in black is over 75 while the shorter 5 minute TM in blue has peaked and dropped from 95 to 60. This is in essence bearish divergence. The other indicator, the mass index, shows the value arriving at the reversal zone where a drop to below 26.5 will be the trigger. Overall, for both fundamental and technical reasons, I will enter a short trade on NVAX expecting a correction / pullback from the pop the stock got after a one-time bonus of a payout for not producing unneeded vaccines.
NASDAQ:NVAXShort
by AwesomeAvani
1
Can NVAX rise again?NVAX has had significant down trending over a wide range of time. On the 4H chart it seems to be pivoting from a swing bottom 3-4 days ago. This is accompanied by a cross of the MACD lines under the histogram on that indicator and a flip of volatility on the relative volatility indicator. NVAX has been subject to significant short selling. Price is presently nearly two standard deviations below the mean anchored VWAP set in mid May. Basically it is in deep undervalued oversold territory and now with a rise. The volume profile has a point of control level considerably above the mean VWAP. This is the level with the highest volume of trades showing most trades occurred well above VWAP. This would be traders taking profit and selling or alternatively short sellers opening a position but more likely a combination of them. Price wants to ascend to at least VWAP if not the POC line. My analysis is that any significant rise could begin a squeeze on short positions. Those closing with a buy to cover trade would in effect be synergizing new buyers and add to the bullish momentum, Accordingly, I will open a position early and see if I can get in ahead of a potential short squeeze. While speculative, a narrow stop loss at 6.80 the second band line below the mean VWAP will take a lot of risk off the trade and allow me to be patient comfortably watching the price action.
NASDAQ:NVAXLong
by AwesomeAvani
8
VAXX Biotech Penny Stock Earnings Play VAXX is a speculative penny biotechnology NASDAQ stock with high volatility. On the 2H chart, it is currently trending up from a swing low on April 25 with earnings to be reported Monday 5/8. May's relative volume compared with that of April is about 2-3X higher. To confirm the bullish bias, VAXX is currently trading above its intermediate-term POC line on the volume profile. This confirms buyers as being in control. Although this is speculative as are all biotechnology penny stocks, impending earnings as a catalyst has been considered. Continued development in the vaccine subsector at large may suggest VAXX may have a favorable report to fuel further price action.
VLong
by AwesomeAvani
NVAX Biotechnology Watch Dead Cat Bounce LONGNVAX is fundamentally weak with a shallow pipeline and no products currenly marketed to fund earnings and so research. On the 15 minute chart , NVAX is seen near to its demand zone as shown by the Luxalgo indicator. In the meanwhile, the RSI indicator shows considerable recent strength which is decreased today. So the question is whether NVAX can dead cat bounce with a potential 20% uptrend to reach the supply one or if it instead will break support and continue its descent from a double top April 14-17. I will watch this for the price action to determine whether to take a long trade or short sell this again. Other " vaccine stocks" may be in action as well including VBIV, VCNX, VAXX and MRNA.
NASDAQ:NVAX
by AwesomeAvani
NVAX - Novavax Biotech Short or not?NVAX as seen on the weekly chart has been in price distress for a long time. It has only one product on the market due to various issues with the FDA process. It has a variety of products in development as linked below. The question is whether it will run out of cash before a sustained revenue stream develops. FDA approvals for the pipeline products could take years ( the days of emergency approvals for COVID and related are over) It would seem that a rich uncle like Moderna ( MRNA) would codcme around with a take-over offer that could send shares into a moonshot to back when NVAX thrived before its 95% price decline in the past two years. This seems to be a great short swing play until more products come to market or a take-over is announced. This is affirmed by the MACD histogram being persistently negative for the long-term.
NASDAQ:NVAXShort
by AwesomeAvani
1
Selling NVAX in corrective channel.Novavax - 30d expiry - We look to Sell at 27.69 (stop at 30.03) The primary trend remains bearish. Trading within a Corrective Channel formation. The trend of higher highs is located at 26.80. Previous support at 27.40 now becomes resistance. We look for a temporary move higher. Preferred trade is to sell into rallies. Our profit targets will be 22.02 and 21.02 Resistance: 21.60 / 23.00 / 25.30 Support: 18.26 / 16.86 / 16.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:NVAXShort
by Saxo
Novavax in a bear flag.Novavax - 30d expiry - We look to Sell a break of 15.49 (stop at 17.01) Daily signals are bearish. There is no clear indication that the downward move is coming to an end. Prices are extending lower from the bearish flag/pennant formation. Posted a bearish Flag formation. A break of 15.50 is needed to confirm the outlook. The bias is to break to the downside. This stock has seen poor sales growth. Our outlook is bearish. Our profit targets will be 12.12 and 11.62 Resistance: 18.00 / 18.55 / 19.50 Support: 16.30 / 15.53 / 15.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:NVAXShort
by Saxo
4
Bullish hammer on Novavax?Novavax Short Term We look to Buy at 35.94 (stop at 32.00) Posted a Bullish Hammer Bottom on the Daily chart. Although the anticipated move higher is corrective, it does offer ample risk/reward today. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Expect trading to remain mixed and volatile. Our profit targets will be 49.43 and 60.00 Resistance: 45.00 / 63.00 / 76.00 Support: 35.00 / 23.12 / 15.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:NVAXLong
by Saxo
6
Is NVAX oversold following its earnings miss?A few days ago, NVAX gapped down 30 percent on a large earnings miss. This means that now NVAX is down over 87% from its ATH. Why I think NVAX is a buy right now The stock had a minor rally off a long term support level extending to 2020, and has higher lows than during the previous rally off this support level. It is trading at a heavily discounted price/sales of 2.55, far below its peak p/s at 249.16. There is a large upside, with the nearest strong resistance level roughly 50% above the current price. I'm buying in at around 42.2 with a high risk reward ratio. I'll be targeting a roughly 20% return with a 5% stop.
NASDAQ:NVAXLong
by spiritualhealer117